Seeking Alpha

Chuck Norris

Chuck Norris
Send Message
View as an RSS Feed
View Chuck Norris' Comments BY TICKER:
Latest  |  Highest rated
  • Pharmacyclics: 7 Different Insiders Have Sold Shares During The Last 30 Days [View article]
    This is easy!
    May 14 12:34 AM | Likes Like |Link to Comment
  • Medivation: Early Launch Of Xtandi Appears Solid [View article]
    Research suggests that corticosteroids (prednisone) activate androgen receptor signaling and actually promote prostate cancer...

    Cancer Res. 2012 May 1;72(9):2176-82. "Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100."

    New data recently presented at the annual GU cancer symposium in February 2013 suggests that concurrent use of prednisone reduces overall survival and increases grade 3-4 adverse events...

    6 Oral Abstract Session A, Thu, 1:15 PM-3:05 PM. "Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.
    Mar 6 11:00 AM | Likes Like |Link to Comment
  • Anthera Shifts Its Strategy For Blisibimod [View article]
    No value assigned to Blisibimod... clearly an active drug with an already clinically validated target in BLyS.

    With a little fortitude, perseverance and a few round-house kicks to the face, the current $50 million market cap may end up looking like quite the bargain in the rear view mirror.

    http://1.usa.gov/10Rfsfl

    http://1.usa.gov/W7nL8v
    Jan 26 06:40 PM | 1 Like Like |Link to Comment
  • As ArQule Investors Panic, Watch Exelixis Too [View article]
    While ARQ197 claimed to be a c-MET inhibitor, its cell-free binding affinity (IC50) for c-MET is >300 nM. This is much higher than all other c-MET inhibitors in development, for instance cabozantinib's cell-free IC50 for c-MET is 1.8 nM.

    It can not be ruled out that the clinical activity seen with the high doses of ARQ197 used in clinical studies could be do to inhibition of kinases other than c-MET.

    Importantly however, positive clinical results with Roche's MetMab (an anti-c-MET antibody), specifically in NSCLC (lung cancer) patients expressing high-levels of c-MET, support c-MET as a valid target in this patient population.
    Oct 4 03:26 PM | Likes Like |Link to Comment
  • The Fed Putting America In A Hole [View article]
    Chuck Norris once commented, "There are few problems in this world that cannot be solved by a swift roundhouse kick to the face. In fact, there are none."
    Aug 29 01:37 AM | 1 Like Like |Link to Comment
COMMENTS STATS
5 Comments
2 Likes